Galectin Aligns with FDA on Belapectin Regulatory Path for MASH Cirrhosis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
Source: NASDAQ.COM
- FDA Meeting Outcome: Galectin Therapeutics achieved alignment with the U.S. FDA during a recent in-person Type C meeting, clarifying the primary endpoint and regulatory path for Belapectin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension, marking a significant advancement in the company's clinical development.
- Phase 3 Trial Plans: The company intends to submit the Phase 3 protocol in Q3 2026, conducting a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Belapectin in preventing disease progression in patients with MASH cirrhosis and portal hypertension, indicating potential benefits for patients.
- Clinical Endpoint Alignment: The FDA and Galectin agreed on a composite clinical endpoint that includes prevention of disease progression and the development of large esophageal varices greater than 5 mm, which is a meaningful indicator of worsening portal hypertension and MASH cirrhosis.
- Dose Evaluation Plan: Based on efficacy observed in prior clinical studies, the company plans to evaluate a single 2mg dose of Belapectin in the Phase 3 trial, aiming to advance clinical progress and attract strategic and financial partnership opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GALT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GALT
Wall Street analysts forecast GALT stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.610
Low
11.00
Averages
11.00
High
11.00
Current: 4.610
Low
11.00
Averages
11.00
High
11.00
About GALT
Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pulsenmore Soars 280% on Ouma Health Collaboration
- Strategic Partnership: Pulsenmore Ltd. has entered into a collaboration with Ouma Health, a provider of virtual maternity care solutions in the U.S., enabling the integration of its FDA-authorized home ultrasound platform, which is expected to significantly enhance customer satisfaction and strengthen market competitiveness.
- Stock Surge: Following the announcement of the partnership, Pulsenmore's stock soared by as much as 280%, closing up 93.26%, reflecting strong market confidence in its future growth potential.
- Technological Innovation: By introducing ultrasound monitoring into homes, Pulsenmore not only increases the frequency of contact between expectant mothers and their care teams but also potentially drives the adoption of virtual healthcare services, aligning with the industry's shift towards digital transformation.
- Market Outlook: This collaboration marks a significant positioning for Pulsenmore in the rapidly growing virtual healthcare market, likely attracting more investor attention and enhancing its standing within the industry.
See More
Boundless Bio Merges with Serapha in All-Stock Deal
- Merger Overview: Boundless Bio has agreed to merge with privately held Serapha Bio in an all-stock transaction expected to close in Q4 2026, with the combined entity to operate under the name Serapha Bio, Inc. and trade on Nasdaq as "AATD", enhancing its competitive position in the biopharmaceutical market.
- Cash Dividend Plan: Prior to the merger's completion, Boundless Bio plans to declare a cash dividend to existing shareholders, aimed at boosting shareholder confidence and laying a solid foundation for the upcoming merger, which is expected to attract more investor interest.
- Clinical Candidate Development: Serapha's lead clinical candidate, SERP-01, is being developed for severe Alpha-1 Antitrypsin Deficiency, which is anticipated to provide new revenue streams for the company and strengthen its market position in the therapeutic area.
- Stock Performance: Boundless Bio's stock surged 85.71% to close at $2.60, reflecting a positive market reaction to the merger news and indicating investor optimism regarding future growth potential.
See More
Galectin Therapeutics Reaches Agreement with FDA for Late-Stage Trial
- FDA Agreement: Galectin Therapeutics has reached an agreement with the U.S. FDA to conduct a late-stage trial for belapectin in patients with MASH cirrhosis and portal hypertension, which is expected to provide a clearer roadmap for potential marketing approval, contributing to a 22% stock price increase on Tuesday.
- Trial Design: The trial will evaluate a single 2 mg dose of belapectin, aiming to prevent esophageal varices, using the same centralized, blinded endoscopy review process as in a previous trial, with a similar expected size, and plans to submit the final protocol to the FDA in Q3 2026.
- Market Sentiment Shift: Over the past 24 hours, retail sentiment around GALT shifted from 'bearish' to 'bullish', with message volume rising from 'normal' to 'high', indicating investor optimism regarding an upcoming partnership announcement and the market potential of belapectin.
- Strategic Partnership Exploration: CEO Joel Lewis noted that the agreement provides “important clarity” and renewed confidence, as Galectin actively seeks strategic partnerships to support the development of belapectin, although approval will follow the traditional full-approval pathway.
See More
Galectin Aligns with FDA on Belapectin Regulatory Path for MASH Cirrhosis
- FDA Meeting Outcome: Galectin Therapeutics achieved alignment with the U.S. FDA during a recent in-person Type C meeting, clarifying the primary endpoint and regulatory path for Belapectin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension, marking a significant advancement in the company's clinical development.
- Phase 3 Trial Plans: The company intends to submit the Phase 3 protocol in Q3 2026, conducting a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Belapectin in preventing disease progression in patients with MASH cirrhosis and portal hypertension, indicating potential benefits for patients.
- Clinical Endpoint Alignment: The FDA and Galectin agreed on a composite clinical endpoint that includes prevention of disease progression and the development of large esophageal varices greater than 5 mm, which is a meaningful indicator of worsening portal hypertension and MASH cirrhosis.
- Dose Evaluation Plan: Based on efficacy observed in prior clinical studies, the company plans to evaluate a single 2mg dose of Belapectin in the Phase 3 trial, aiming to advance clinical progress and attract strategic and financial partnership opportunities.
See More
Galectin Reaches Agreement with FDA on Phase 3 Trial for Belapectin
- FDA Agreement: Galectin Therapeutics announced an agreement with the FDA to conduct a Phase 3 trial testing its lead asset belapectin for cirrhosis and portal hypertension linked to metabolic dysfunction-associated steatohepatitis, marking a significant advancement in drug development.
- Trial Design Confirmation: The FDA has agreed to key components of the Phase 3 program, including its design and primary endpoint, paving the way for potential full approval of belapectin, despite the previous Phase 2b/3 trial failing to meet its primary endpoint.
- Negative Market Reaction: Despite the agreement, Galectin's shares fell approximately 9% in premarket trading, reflecting market concerns regarding the company's future clinical trial outcomes, which could impact investor confidence.
- Future Plans: The company expects the planned study to be comparable in size to the NAVIGATE trial, targeting similar patient types, with the final Phase 3 protocol submission anticipated in Q3 2026, demonstrating the company's ongoing commitment to future research.
See More
Galectin Reaches Key Agreement with FDA on Belapectin Approval Path
- FDA Agreement: Galectin has reached an agreement with the FDA on the primary endpoint and regulatory pathway for belapectin, marking a significant advancement in the treatment of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis, which is expected to enhance its market competitiveness.
- Phase 3 Trial Plans: The company intends to submit the Phase 3 protocol in Q3 2026 to assess the safety and efficacy of belapectin in preventing disease progression in MASH cirrhosis patients, demonstrating a commitment to addressing substantial unmet medical needs.
- Clinical Assessment Methodology: The FDA accepted the company's proposed blinded central endoscopy review process, ensuring standardized and consistent assessment of esophageal varices across global studies, thereby enhancing the scientific rigor of the clinical trial.
- Strategic Partnership Opportunities: Galectin is actively exploring strategic and financial partnerships to support the continued development and commercialization of belapectin, reflecting the company's confidence in future growth and focus on patient needs.
See More
Pulsenmore Soars 280% on Ouma Health Collaboration
- Strategic Partnership: Pulsenmore Ltd. has entered into a collaboration with Ouma Health, a provider of virtual maternity care solutions in the U.S., enabling the integration of its FDA-authorized home ultrasound platform, which is expected to significantly enhance customer satisfaction and strengthen market competitiveness.
- Stock Surge: Following the announcement of the partnership, Pulsenmore's stock soared by as much as 280%, closing up 93.26%, reflecting strong market confidence in its future growth potential.
- Technological Innovation: By introducing ultrasound monitoring into homes, Pulsenmore not only increases the frequency of contact between expectant mothers and their care teams but also potentially drives the adoption of virtual healthcare services, aligning with the industry's shift towards digital transformation.
- Market Outlook: This collaboration marks a significant positioning for Pulsenmore in the rapidly growing virtual healthcare market, likely attracting more investor attention and enhancing its standing within the industry.
See More
Boundless Bio Merges with Serapha in All-Stock Deal
- Merger Overview: Boundless Bio has agreed to merge with privately held Serapha Bio in an all-stock transaction expected to close in Q4 2026, with the combined entity to operate under the name Serapha Bio, Inc. and trade on Nasdaq as "AATD", enhancing its competitive position in the biopharmaceutical market.
- Cash Dividend Plan: Prior to the merger's completion, Boundless Bio plans to declare a cash dividend to existing shareholders, aimed at boosting shareholder confidence and laying a solid foundation for the upcoming merger, which is expected to attract more investor interest.
- Clinical Candidate Development: Serapha's lead clinical candidate, SERP-01, is being developed for severe Alpha-1 Antitrypsin Deficiency, which is anticipated to provide new revenue streams for the company and strengthen its market position in the therapeutic area.
- Stock Performance: Boundless Bio's stock surged 85.71% to close at $2.60, reflecting a positive market reaction to the merger news and indicating investor optimism regarding future growth potential.
See More
Galectin Therapeutics Reaches Agreement with FDA for Late-Stage Trial
- FDA Agreement: Galectin Therapeutics has reached an agreement with the U.S. FDA to conduct a late-stage trial for belapectin in patients with MASH cirrhosis and portal hypertension, which is expected to provide a clearer roadmap for potential marketing approval, contributing to a 22% stock price increase on Tuesday.
- Trial Design: The trial will evaluate a single 2 mg dose of belapectin, aiming to prevent esophageal varices, using the same centralized, blinded endoscopy review process as in a previous trial, with a similar expected size, and plans to submit the final protocol to the FDA in Q3 2026.
- Market Sentiment Shift: Over the past 24 hours, retail sentiment around GALT shifted from 'bearish' to 'bullish', with message volume rising from 'normal' to 'high', indicating investor optimism regarding an upcoming partnership announcement and the market potential of belapectin.
- Strategic Partnership Exploration: CEO Joel Lewis noted that the agreement provides “important clarity” and renewed confidence, as Galectin actively seeks strategic partnerships to support the development of belapectin, although approval will follow the traditional full-approval pathway.
See More
Galectin Aligns with FDA on Belapectin Regulatory Path for MASH Cirrhosis
- FDA Meeting Outcome: Galectin Therapeutics achieved alignment with the U.S. FDA during a recent in-person Type C meeting, clarifying the primary endpoint and regulatory path for Belapectin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension, marking a significant advancement in the company's clinical development.
- Phase 3 Trial Plans: The company intends to submit the Phase 3 protocol in Q3 2026, conducting a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Belapectin in preventing disease progression in patients with MASH cirrhosis and portal hypertension, indicating potential benefits for patients.
- Clinical Endpoint Alignment: The FDA and Galectin agreed on a composite clinical endpoint that includes prevention of disease progression and the development of large esophageal varices greater than 5 mm, which is a meaningful indicator of worsening portal hypertension and MASH cirrhosis.
- Dose Evaluation Plan: Based on efficacy observed in prior clinical studies, the company plans to evaluate a single 2mg dose of Belapectin in the Phase 3 trial, aiming to advance clinical progress and attract strategic and financial partnership opportunities.
See More
Galectin Reaches Agreement with FDA on Phase 3 Trial for Belapectin
- FDA Agreement: Galectin Therapeutics announced an agreement with the FDA to conduct a Phase 3 trial testing its lead asset belapectin for cirrhosis and portal hypertension linked to metabolic dysfunction-associated steatohepatitis, marking a significant advancement in drug development.
- Trial Design Confirmation: The FDA has agreed to key components of the Phase 3 program, including its design and primary endpoint, paving the way for potential full approval of belapectin, despite the previous Phase 2b/3 trial failing to meet its primary endpoint.
- Negative Market Reaction: Despite the agreement, Galectin's shares fell approximately 9% in premarket trading, reflecting market concerns regarding the company's future clinical trial outcomes, which could impact investor confidence.
- Future Plans: The company expects the planned study to be comparable in size to the NAVIGATE trial, targeting similar patient types, with the final Phase 3 protocol submission anticipated in Q3 2026, demonstrating the company's ongoing commitment to future research.
See More
Galectin Reaches Key Agreement with FDA on Belapectin Approval Path
- FDA Agreement: Galectin has reached an agreement with the FDA on the primary endpoint and regulatory pathway for belapectin, marking a significant advancement in the treatment of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis, which is expected to enhance its market competitiveness.
- Phase 3 Trial Plans: The company intends to submit the Phase 3 protocol in Q3 2026 to assess the safety and efficacy of belapectin in preventing disease progression in MASH cirrhosis patients, demonstrating a commitment to addressing substantial unmet medical needs.
- Clinical Assessment Methodology: The FDA accepted the company's proposed blinded central endoscopy review process, ensuring standardized and consistent assessment of esophageal varices across global studies, thereby enhancing the scientific rigor of the clinical trial.
- Strategic Partnership Opportunities: Galectin is actively exploring strategic and financial partnerships to support the continued development and commercialization of belapectin, reflecting the company's confidence in future growth and focus on patient needs.
See More
